Results 71 to 80 of about 1,789 (171)

Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2017
Objective: To evaluate the potential for a clinically relevant drug–drug interaction with concomitant use of a dapivirine vaginal ring, a novel antiretroviral-based HIV-1 prevention strategy, and hormonal contraception by examining contraceptive efficacies with and without dapivirine ring use ...
Jennifer E, Balkus, Thesla, Palanee-Phillips, Krishnaveni, Reddy, Samantha, Siva, Ishana, Harkoo, Clemensia, Nakabiito, Kenneth, Kintu, Gonasangrie, Nair, Catherine, Chappell, Flavia Matovu, Kiweewa, Samuel, Kabwigu, Logashvari, Naidoo, Nitesha, Jeenarain, Mark, Marzinke, Lydia, Soto-Torres, Elizabeth R, Brown, Jared M, Baeten   +16 more
openaire   +2 more sources

Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy. [PDF]

J Acquir Immune Defic Syndr, 2018
Background: Monthly use of the dapivirine vaginal ring has been shown to be safe and effective for HIV-1 prevention in nonpregnant reproductive-aged women. The impact of dapivirine on pregnancy outcomes and infant is not known.
Makanani B, Balkus JE, Jiao Y, Noguchi LM, Palanee-Phillips T, Mbilizi Y, Moodley J, Kintu K, Reddy K, Kabwigu S, Jeenariain N, Harkoo I, Mgodi N, Piper J, Rees H, Scheckter R, Beigi R, Baeten JM.   +17 more
europepmc   +4 more sources

Recent advances in pre-exposure prophylaxis for HIV [PDF]

, 2017
Although pre-exposure prophylaxis (PrEP)-the use of antiretroviral drugs by non-infected people to prevent the acquisition of HIV-is a promising preventive option, important public health questions remain.
Desai, M, Field, N, Grant, R, McCormack, S   +3 more
core   +1 more source

Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
Variable adherence limits effectiveness of daily oral and intravaginal tenofovir-containing pre-exposure prophylaxis. Monthly vaginal antiretroviral rings are one approach to improve adherence and drug delivery.MTN-013/IPM 026, a multisite, double-blind, randomized, placebo-controlled trial in 48 HIV-negative US women, evaluated vaginal rings ...
Beatrice A, Chen, Lori, Panther, Mark A, Marzinke, Craig W, Hendrix, Craig J, Hoesley, Ariane, van der Straten, Marla J, Husnik, Lydia, Soto-Torres, Annalene, Nel, Sherri, Johnson, Nicola, Richardson-Harman, Lorna K, Rabe, Charlene S, Dezzutti   +12 more
openaire   +2 more sources

Attitudes and perceptions towards novel objective measures of ARV-based vaginal ring use: Results from a global stakeholder survey.

PLoS ONE, 2017
Results of recent microbicide and pre-exposure prophylaxis clinical trials have shown adherence to be a significant challenge with new HIV prevention technologies.
Randy M Stalter, Jenae Tharaldson, Derek H Owen, Eunice Okumu, Thomas Moench, Natasha Mack, Elizabeth E Tolley, Kathleen M MacQueen   +7 more
doaj   +1 more source

How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub‐Saharan Africa: a mixed methods analysis

Journal of the International AIDS Society, 2023
Introduction Effective use of pre‐exposure prophylaxis (PrEP) has been low among adolescent girls and young women (AGYW) in sub‐Saharan Africa. The MTN‐034/REACH trial offered AGYW a menu of adherence support strategies and achieved high adherence to ...
Sarah T. Roberts, Noah Mancuso, Kristin Williams, Hadijah Kalule Nabunya, Hlengiwe Mposula, Caroline Mugocha, Priscilla Mvinjelwa, Morgan Garcia, Daniel W. Szydlo, Lydia Soto‐Torres, Kenneth Ngure, Sybil Hosek   +11 more
doaj   +1 more source

PrEParing for choice in a new era of HIV prevention [PDF]

, 2023
In The Lancet HIV, Gonasagrie Nair and colleagues1 report the findings from the MTN-34/REACH trial, which investigated the safety of, adherence to, and preferences for HIV pre-exposure prophylaxis (PrEP) among adolescent girls and young women.
Chi, Benjamin H, Graybill, Lauren A
core   +2 more sources

Multipurpose Prevention Technologies: Oral, Parenteral, and Vaginal Dosage Forms for Prevention of HIV/STIs and Unplanned Pregnancy [PDF]

, 2021
There is a high global prevalence of HIV, sexually transmitted infections (STIs), and unplanned pregnancies. Current preventative daily oral dosing regimens can be ineffective due to low patient adherence.
Benhabbour, Soumya Rahima, Young, Isabella C.   +1 more
core   +2 more sources

Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2020
Background: Young women aged 15–24 years are disproportionately affected by the HIV epidemic. Two phase III trials of a vaginal ring containing 25-mg dapivirine demonstrated HIV-1 risk reduction in adult women older than 21 years but not in those aged 18–21 years. Lack of protection was correlated with low adherence.
Bunge, Katherine E, Levy, Lisa, Szydlo, Daniel W, Zhang, Jingyang, Gaur, Aditya H, Reirden, Daniel, Mayer, Kenneth H, Futterman, Donna, Hoesley, Craig, Hillier, Sharon L, Marzinke, Mark A, Hendrix, Craig W, Gorbach, Pamina M, Wilson, Craig M, Soto-Torres, Lydia, Kapogiannis, Bill, Nel, Annalene, Squires, Kathleen E, MTN-023/IPM 030 Study Team   +18 more
openaire   +4 more sources

Traditional health practitioners’ management of HIV/AIDS in rural South Africa in the era of widespread antiretroviral therapy [PDF]

, 2017
Background: Traditional health practitioners (THPs) have been identified as a key local resource in the fight against HIV/AIDS in South Africa. However, their approaches to the treatment of people living with HIV (PLHIV) have been met with skepticism by ...
Moshabela, Mosa, Rochat, Tamsen, Wight, Daniel, Zuma, Thembelihle   +3 more
core   +1 more source